Belite Bio, Inc
corporate_fare Company Profile
Belite Bio, Inc (NASDAQ:BLTE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for BLTE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for BLTE spans 6-K, 144, 20-F.
Recent high-impact activity:
- FDA Extends Tinlarebant NDA Review by Three Months; PDUFA Date Now May 12, 2027
- FDA Pushes Tinlarebant Decision Back Three Months to May 2027
- Belite Bio Q3: FDA Skips Adcom for Tinlarebant NDA, PDUFA Set for February 12, 2027
- Belite Bio Submits NDA in Japan for Tinlarebant Under Sakigake Designation
- Q2 2026 Results: Net Loss Widens to $28.4M, Yet Cash Position Remains Strong at $780M
Financial Snapshot
Short Interest & Short Volume
9.96 days to coverFINRA reported short interest of 1,380,466 shares in BLTE as of the October 30, 2026 settlement, a 8.9% increase from the prior period — about 10.0 days to cover at its recent average daily volume. On November 20, 2026, 65.7% of BLTE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BLTE, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.
Warrant Shares Re-Registered · Minimal Proceeds at Stake
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BLTE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.